LungLife AI, Inc.
(the "Company" or "LungLife")
Result of Annual General Meeting
LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, announces that at its Annual General Meeting, held at earlier today, all 10 resolutions put to members were passed on a poll.
The number of votes lodged by proxy for and against each of the resolutions proposed, and the number of votes withheld was as follows:
| Resolution | Votes for | % | Votes against | % | Votes withheld |
| Resolution 1 (Common) TO receive the Annual Report and Accounts of the Company for the year ended 31 December 2022 together with the directors' and auditor's reports thereon. | 13,016,289 | 100.00 | 0 | 0.00 | 0 |
| Resolution 2 (Common) TO approve the Directors' Remuneration Policy. | 9,997,926 | 76.81 | 3,018,363 | 23.19 | 0 |
| Resolution 3 (Common) TO receive the Directors' Remuneration Report for the year ended 31 December 2022. | 13,016,289 | 100.00 | 0 | 0.00 | 0 |
| Resolution 4 (Common) THAT Roy Davis be, and hereby is, re-elected as a director of the Company to hold office until the conclusion of the next Annual General Meeting of the Company. | 13,016,289 | 100.00 | 0 | 0.00 | 0 |
| Resolution 5 (Common) THAT Paul Pagano be, and hereby is, re-elected as a director of the Company to hold office until the conclusion of the next Annual General Meeting of the Company. | 13,016,289 | 100.00 | 0 | 0.00 | 0 |
| Resolution 6 (Common) THAT David Anderson be, and hereby is, re-elected as a director of the Company to hold office until the conclusion of the next Annual General Meeting of the Company. | 13,016,289
| 100.00 | 0 | 0.00 | 0 |
| Resolution 7 (Common) THAT Andrew Boteler be, and hereby is, re-elected as a director of the Company to hold office until the conclusion of the next Annual General Meeting of the Company. | 13,016,289
| 100.00 | 0 | 0.00 | 0 |
| Resolution 8 (Common) THAT Sara Barrington be, and hereby is, re-elected as a director of the Company to hold office until the conclusion of the next Annual General Meeting of the Company. | 13,016,289
| 100.00 | 0 | 0.00 | 0 |
| Resolution 9 (Common) THAT James McCullough be, and hereby is, re-elected as a director of the Company to hold office until the conclusion of the next Annual General Meeting of the Company. | 13,016,289 | 100.00 | 0 | 0.00 | 0 |
| Resolution 10 (Common) THAT Crowe UK LLP be, and hereby is, reappointed as auditor of the Company to hold office until the conclusion of the next Annual General Meeting of the Company. | 13,016,289 | 100.00 | 0 | 0.00 | 0 |
The Company notes that, whilst Resolution 2 was passed with the required majority, there was a sizable vote against it representing 23.19% of shareholders who voted. The Company acknowledges these votes and will engage with shareholders to understand further the reasons behind this vote. The Board will provide an update on this engagement and any actions taken will be published within six months of the AGM.
As at 4 May 2023, there were 25,485,982 common shares in issue. Stockholders are entitled to one vote per common share. Votes withheld are not votes in law and so have not been included in the calculation of the proportion of votes for and against a resolution.
For further information please contact:
| LungLife AI, Inc. | |
| Paul Pagano, CEO | Via Walbrook PR |
| David Anderson, CFO |
|
|
|
|
| Investec Bank plc (Nominated Adviser & Joint Broker) | Tel: +44 (0)20 7597 5970 |
| Virginia Bull / Cameron MacRitchie / Lydia Zychowska | |
|
Goodbody (Joint Broker) Tom Nicholson / Stephen Kane |
Tel: +44 (0) 20 3841 6202 / +353 (1) 667 0420 |
| | |
| Walbrook PR Limited | Tel: +44 (0)20 7933 8780 or LungLifeAI@walbrookpr.com |
| Stephanie Cuthbert / Alice Woodings / Phillip Marriage | Mob: 07980 541 893 / 07407 804 654 / 07867 984 082 |
About Lunglife AI
LungLife AI is a developer of clinical diagnostic solutions designed to make a significant impact in the early detection of lung cancer, the deadliest cancer globally. Using a minimally invasive blood draw, the Company's LungLB® test is designed to deliver additional information to clinicians who are evaluating indeterminate lung nodules. For more information visit www.lunglifeai.com. Our Purpose is to be a driving force in the early detection to lung cancer. Our Vision is to invert the 20:80 ratio such that in years to come at least 80% of lung cancer is detected early.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.